Pozniak A - Search Results

1

HIV-associated neurocognitive disease: case studies and suggestions for diagnosis and management in different patient subgroups.

Pozniak A, Rackstraw S, Deayton J, Barber T, Taylor S, Manji H, Melvin D, Croston M, Nightingale S, Kulasegaram R, Pitkanen M, Winston A. Pozniak A, et al. Antivir Ther. 2014;19(1):1-13. doi: 10.3851/IMP2563. Epub 2013 Mar 21. Antivir Ther. 2014. PMID: 23519006 Review.

2

Mycobacterial diseases and HIV.

Pozniak A. Pozniak A. J HIV Ther. 2002 Feb;7(1):13-6. J HIV Ther. 2002. PMID: 11956499 Review.

3

The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.

Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG. Sproat M, et al. Antivir Ther. 2005;10(2):357-61. Antivir Ther. 2005. PMID: 15865231

4

Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis.

Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Michailidis C, et al. Antivir Ther. 2005;10(3):417-22. doi: 10.1177/135965350501000303. Antivir Ther. 2005. PMID: 15918332

5

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.

Winston A, Back D, Fletcher C, Robinson L, Unsworth J, Tolowinska I, Schutz M, Pozniak AL, Gazzard B, Boffito M. Winston A, et al. Among authors: pozniak al. AIDS. 2006 Jun 26;20(10):1401-6. doi: 10.1097/01.aids.0000233573.41597.8a. AIDS. 2006. PMID: 16791014

6

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.

Dunn D, Geretti AM, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin C, Phillips A; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study. Dunn D, et al. Among authors: pozniak a. Antivir Ther. 2008;13(6):771-7. Antivir Ther. 2008. PMID: 18839778

7

New drugs.

Pozniak A. Pozniak A. J HIV Ther. 2008 Jun;13(2):27-33. J HIV Ther. 2008. PMID: 18953271 No abstract available.

8

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.

Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G. Boffito M, et al. Among authors: pozniak a. Antivir Ther. 2008;13(7):901-7. Antivir Ther. 2008. PMID: 19043924 Clinical Trial.

9

Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.

Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study. Price H, et al. Among authors: pozniak a. Antivir Ther. 2010;15(2):203-11. doi: 10.3851/IMP1511. Antivir Ther. 2010. PMID: 20386075

10

HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom.

Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B, Pillay D, Dunn DT; UK Collaborative Group on HIV Drug Resistance. Chilton DN, et al. Antivir Ther. 2010;15(7):985-91. doi: 10.3851/IMP1658. Antivir Ther. 2010. PMID: 21041913

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

557 results

Search Page

Filters